You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Illumina said that the DTC market is in "transition" from ancestry and genealogy to one driven by demand for health information.
The company published a letter on its website explaining that the genetic and other analyses involved in its services were too costly for customers to support.
Patients within the project and their physicians will be able to access Genome Medical's genetic specialists to address concerns and incorporate genetic information into care.
My Gene Counsel's confirmatory testing program is the latest example of how the healthcare system is adapting to consumers' growing appetite for genetic testing.
Healthcare providers continue to worry about the impact of 23andMe's health risk reports but there is also growing acceptance of the DTC testing model.
The new channel, to be launched in the second quarter, is part of the company's plan to make genetic testing affordable and accessible to everyone.
Direct-to-consumer genetic testing firm 23andMe has a newly cleared colorectal cancer risk test.
LunaDNA parent company LunaPBS will combine its technology platform with Genetic Alliance's PEER system to advance patient-centric research.
In an effort to lift patient access barriers, the company is launching a model whereby consumers will be able to initiate test orders online.
Blockchain-based startup EncrypGen will take advantage of Murrieta Genomics' sequencing lab and business services to market its Gene-Chain platform for data sharing.
Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.
Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.
The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.
In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.